Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

Alnylam was founded in Cambridge, Massachusetts in 2002 by a group of venture investors and scientists—including Paul Schimmel, Phillip Sharp, and David Bartel—with the specific mandate of turning RNA interference into human therapeutics. John Maraganore joined shortly after and served as CEO for 19 years, steering the company from early-stage research through a 2004 IPO, multiple clinical setbacks, and eventually the FDA approval of ONPATTRO in 2018 — the first-ever RNAi drug. The company occupies a unique position as the only vertically integrated, fully independent leader in RNAi, distinct from antisense oligonucleotide players like Ionis or nucleic acid-based vaccine makers like Moderna. Alnylam operates a dual-platform strategy combining rare-disease commercial products with a broad pipeline in highly prevalent conditions. Its current product portfolio includes ONPATTRO, GIVLAARI, OXLUMO, and AMVUTTRA — all targeting genetic diseases with limited or no prior treatment options. The pipeline extends into zilebesiran (hypertension, partnered with Roche) and ALN-APP (early Alzheimer's disease), moving RNAi into massive patient populations. Geographically, the company markets its drugs primarily in the United States and Western Europe, with Alnylam holding global commercial rights or maintaining profit-split agreements with partners like Sanofi. The firm's R&D spend consistently exceeds $1B annually, funded by product revenues and milestone payments from its pharmaceutical collaborations. Alnylam employs over 2,000 people, largely concentrated at its Cambridge headquarters and a growing base in Maidenhead, UK. In 2021, Yvonne Greenstreet assumed the CEO role as Maraganore transitioned to advisory and venture-investing roles through his firm, JMM Innovations. The company maintains a robust patent estate on lipid nanoparticle and conjugate delivery technologies, which it selectively licenses to peers. November 2023: Alnylam reported positive Phase 3 data for vutrisiran in ATTR amyloidosis with cardiomyopathy, positioning the drug for a label expansion into a blockbuster indication (per the firm, November 2023). Alnylam's structural differentiator is its command of the fundamental delivery chemistry that makes RNAi work in the liver and increasingly beyond it. Unlike most biotech platforms, Alnylam owns the full stack — the siRNA design, the GalNAc conjugate technology, the manufacturing process, and the direct commercial infrastructure. This vertical integration means the company captures nearly the full value of approved products while using partnerships selectively for targets outside its commercial footprint. Its governance is a blend of academic founder influence, long-tenured executive leadership, and a board that includes both venture-capital veterans and career pharmaceutical operators.